| chips_act_grants |
$6.4B total CHIPS Act grants |
Up to $6.4B in direct funding for Idaho, New York, and Virginia fabs (amended June 2025) |
| customer_concentration |
16% from one customer (9M YTD) |
One customer accounted for 16% of 9-month revenue, primarily in CNBU segment |
| patent_license_charge |
$57M |
Patent license charges recognized in Q3 FY2025 in other operating expense |
| consideration_payable_to_customers |
$807M |
Estimates for pricing adjustments and returns included in other current liabilities |
| effective_tax_rate |
11.1% |
Q3 FY2025 effective tax rate; tax incentives reduced provision by $240M ($0.21/share) |
| dividend_per_share |
$0.115 |
Quarterly dividend of $0.115 per share |
| stock_buyback_remaining |
$2.81B remaining of $10B authorization |
$7.19B repurchased cumulatively; no repurchases in first 9 months of FY2025 due to CHIPS Act restrictions |
| net_capex_fy2025_guidance |
~$14B |
FY2025 PP&E capex net of government incentive proceeds estimated at ~$14B |
| debt_repayments_note |
$3,604M (9-month YTD) |
Includes prepayment of 2026 Notes, 2026 Term Loan A, 2027 Notes, and 2027 Term Loan A |
| depreciation_amortization_note |
$6,203M (9-month YTD) |
Depreciation expense and amortization of intangible assets from cash flow statement; quarterly breakdown not separately disclosed |
| share_buyback_note |
$0 |
No shares repurchased in first 9 months of FY2025 due to CHIPS Act restrictions |